Cover Image
市場調查報告書

全球酵素抑制劑市場

Global Markets for Enzyme Inhibitors

出版商 BCC Research 商品編碼 243850
出版日期 內容資訊 英文 246 Pages
訂單完成後即時交付
價格
Back to Top
全球酵素抑制劑市場 Global Markets for Enzyme Inhibitors
出版日期: 2017年12月29日 內容資訊: 英文 246 Pages
簡介

全球酵素抑制劑市場預測將從2017年的1,680億美元以年複合成長率1.4%擴大,到2022年前達到1,799億美元的規模。

本報告提供全球酵素抑制劑市場相關調查,彙整市場概要和到2022年的成長預測,產業結構,用途,專利概要,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 摘要和亮點

第3章 市場及技術背景

  • 定義
  • 酵素
    • 特異性
    • 酵素作用的影響因素
    • 酵素的分類
    • 人體的酵素
  • 酵素抑制劑
    • 酵素抑制劑的使用
    • 酵素抑制劑的結構
    • 酵素抑制劑的種類
    • 酵素抑制劑的分類
  • 市場區隔

第4章 技術類型,各地區市場

  • 各類型市場
    • 收益
    • 市場佔有率
  • 各地區市場

第5章 各用途市場

  • 市場佔有率
    • 心血管疾病
    • 消化器官疾病
    • 後天性免疫機能喪失症候群
    • 肝炎
    • 癌症
    • 男性的勃起障礙/良性前列腺肥大症/脫髮症
    • 糖尿病
    • 其他

第6章 產業結構

第7章 專利檢討/新開發

  • 專利
  • 新產品開發

第8章 市場機會分析

  • 促進要素
    • 高齡化
    • 疾病發病率上升
    • 醫療支出增加
    • D2C廣告
    • 新/開發中產品
    • 新的適應
    • 合併和聯合
  • 阻礙要素
    • 專利的失效
    • 政府的法規
    • 價格檢查
  • 機會
    • 新興市場
    • 政府的政策
    • 研究開發
    • 技術創新
    • OTC交換器
  • 課題
    • 變化的法律制度/市場變動
    • 藥物開發的不確定性
    • 品管
    • 專利訴訟

第9章 企業簡介

BCC 關於Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO057C

Report Highlights

The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.

Report Includes:

  • An overview of the global markets for enzyme inhibitors.
  • Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Detailed analysis of the enzyme inhibitors industry structure.
  • A look at applications for enzyme inhibitors, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors.
  • Coverage of significant patents and their allotments in each category.
  • Profiles of major players in the industry.

Report Scope

Enzyme inhibitors drugs are drugs that help to treat chronic diseases such as cardiovascular disease, gastrointestinal disease, acquired immunodeficiency syndrome, cancer, hepatitis, men's-health-related conditions (erectile dysfunction, benign prostatic hyperplasia, alopecia), diabetes and various others (rheumatoid arthritis, psoriasis, Parkinson's disease, influenza, etc.). This report focuses on the global market of enzyme inhibitor drug products and provides an updated review including its applications in various arenas of disease sectors. The scope of the study is global. BCC Research analyzes each market and its application, new products and advancements, market projections and market shares. This study surveys each market in all the geographic regions including North America, Europe and emerging markets. The emerging market category covers all countries such as India, China, South Korea, Taiwan, Africa, Australia, New Zealand, Canada, Latin America and so forth.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the enzyme inhibitor drugs industry. Some of the major players of the market include, F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., AstraZeneca plc, Merck & Co., Gilead Sciences, Janssen Pharmaceuticals, ViiV Healthcare, Eli Lilly and Co., Takeda Pharmaceuticals, Bayer AG, Amgen Inc., AbbVie , Eisai Inc., Teva Pharmaceuticals Inc. and others.

BCC Research analyzes the current market situation by discussing the market drivers, restraints, challenges and opportunities. The market projections and market shares are examined for each region and type. The latest news pieces including new products, mergers and acquisitions in each market are also dealt with in sufficient detail. Also included in the report are relevant patent analysis and comprehensive profiles of companies that are dominant in the enzyme inhibitors industry.

The period of the current report saw an enormous number of new approvals and new indication approvals. New enzyme inhibitor categories gained entries in the market. In comparison with the last report, therefore, a number of new enzyme inhibitor types have been included in this report. They are integrase inhibitors, PCSK9 inhibitors, PARP inhibitors, PDE4 inhibitors, DPP-4 inhibitors and SGLT-2 inhibitors. Certain other categories that had mentionable markets were also included such as AChEIs, 5-ARI inhibitors, XOIs and MAOIs. The market had started to decline due to patent expiries since 2010-2011, and the trend was seen to accelerate during the period of the current report.

Excluded from this report are enzyme inhibitors used in other markets of diagnostics, pesticides and biotechnology.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Definitions
    • Enzymes
    • Coenzymes
    • Cofactor
    • Active Site
    • Substrate
    • Enzyme Inhibitors
  • Enzymes
    • Enzyme Specificity
    • Factors Affecting Enzymatic Action
    • Classification of Enzymes
    • Enzymes in the Human Body
  • Enzyme Inhibitors
    • Uses of Enzyme Inhibitors
    • Mechanism of Enzyme Inhibitors
    • Types of Enzyme Inhibitors
    • Classification of Enzyme Inhibitors
  • Market Segments
    • Proton Pump Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
    • Kinase Inhibitors
    • Statins
    • Aromatase Inhibitors
    • Phosphodiesterase Type 4 Inhibitors
    • Phosphodiesterase Type 5 Inhibitors
    • Neuraminidase Inhibitors
    • Angiotensin-Converting Enzyme Inhibitors
    • Poly(ADP-ribose) Polymerase Inhibitors
    • Xanthine Oxidase Inhibitors
    • COX-2 Inhibitors
    • 5-Alpha Reductase Inhibitors
    • Dipeptidyl Peptidase-4 Inhibitors or Gliptins
    • Sodium-Glucose Co-Transporter-2 Inhibitors or Gliflozins
    • Integrase Inhibitors
    • Monoamine Oxidase Inhibitors (MOAIs)
    • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
    • Acetylcholinesterase Inhibitors
    • Aldose Reductase Inhibitors

Chapter 4: Market Breakdown by Technology Type and Region

  • Market by Type
    • Market Revenue
    • Market Share of Enzyme Inhibitors by Type
  • Market by Region
    • Market Overview
    • Market Revenue
    • Market Share
    • Proton Pump Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
    • Kinase Inhibitors
    • Statins
    • Aromatase Inhibitors
    • Phosphodiesterase Type 5 Inhibitors
    • Neuraminidase Inhibitors
    • Angiotensin-Converting Enzyme Inhibitors
    • Poly(ADP-Ribose) Polymerase Inhibitors
    • Xanthine Oxidase Inhibitors
    • Phosphodiesterase 4 Inhibitors
    • Cyclooxygenase Inhibitors
    • 5-Alpha Reductase Inhibitors
    • Dipeptidyl Peptidase-4 Inhibitors
    • Sodium-Glucose Co-Transporter-2 Inhibitors
    • Integrase Inhibitors
    • Monoamine Oxidase Inhibitors
    • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
    • Acetylcholinesterase Inhibitors

Chapter 5: Market Breakdown by Application

  • Global Market Share of Enzyme Inhibitors by Application
    • Cardiovascular Disease
    • Gastrointestinal Disorders
    • Acquired Immunodeficiency Syndrome
    • Hepatitis
    • Cancer
    • Men's Health-Erectile Dysfunction/Benign Prostatic Hyperplasia/Alopecia
    • Diabetes
    • Others

Chapter 6: Industry Structure

  • Proton Pump Inhibitors
    • Market Leaders
    • Market Shares
  • Protease Inhibitors
    • Market Leaders
    • Market Shares
  • Reverse Transcriptase Inhibitors
    • Market Leaders
    • Market Shares
  • Kinase Inhibitors
    • Market Leaders
    • Market Shares
  • Statins
    • Market Leaders
    • Market Shares
  • Aromatase Inhibitors
    • Market Leaders
    • Market Shares
  • Phosphodiesterase Type 5 Inhibitors
    • Market Leaders
    • Market Shares
  • Neuraminidase Inhibitors
    • Market Leaders
    • Market Shares
  • Angiotensin-Converting Enzyme Inhibitors
    • Market Leaders
    • Market Shares
  • Poly(ADP-Ribose) Polymerase Inhibitors
    • Market Leaders
    • Market Shares
  • Xanthine Oxidase Inhibitors
    • Market Leaders
    • Market Shares
  • Phosphodiesterase Type 4 Inhibitors
    • Market Leaders
    • Market Shares
  • Cyclooxygenase Inhibitors
    • Market Leaders
    • Market Shares
  • 5-Alpha Reductase Inhibitors
    • Market Leaders
    • Market Shares
  • Dipeptidyl Peptidase-4 Inhibitors
    • Market Leaders
    • Market Shares
  • Sodium-Glucose Co-Transporter-2 Inhibitors
    • Market Leaders
    • Market Shares
  • Integrase Inhibitors
    • Market Leaders
    • Market Shares
  • Monoamine Oxidase Inhibitors
    • Market Leaders
    • Market Shares
  • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
    • Market Leaders
    • Market Shares
  • Acetylcholinesterase Inhibitors
    • Market Leaders
    • Market Shares

Chapter 7: Patent Review/ New Developments

  • Patents
    • Patents by Year
    • Patents by Type
    • Patents by Company
    • Patents by Country
    • Patents by Assignee
  • New Product Developments
    • New Drug Approvals for Enzyme Inhibitors
    • Pipeline Products for Enzyme Inhibitors
    • Mergers and Acquisitions

Chapter 8 Analysis of Market Opportunities

  • Drivers of Enzyme Inhibitors Market
    • Increasing Aging Population
    • Increasing Incidence of Diseases
    • Rise in Healthcare Spending
    • Direct-to-Consumer Advertising
    • New/Pipeline Products
    • New Indications
    • Mergers and Alliances
  • Restraints of Enzyme Inhibitors Market
    • Patent Expirations
    • Government Regulations
    • Price Checks
  • Opportunities for Enzyme Inhibitors Market
    • Emerging Markets
    • Favorable Government Policies
    • Research and Development
    • Innovation
    • Prescription to Over-the-Counter Switch
  • Challenges for Enzyme Inhibitors Market
    • Changing Regulatory Landscape/Market Fluctuations
    • Uncertainties in Drug Development
    • Quality Control
    • Patent Litigation

Chapter 9: Company Profiles

  • Appendix: Abbreviations

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Enzyme Inhibitors, by Type, Through 2022 ($ Millions)
    • Table 1 Development of ACE Inhibitors
    • Table 2 Patent Expiries of Important Enzyme Inhibitors from 2013 to 2020
    • Table 3 Global Market for Enzyme Inhibitors, by Type, Through 2022 ($ Millions)
    • Table 4 Global Market Share of Enzyme Inhibitors, by Type, 2016 (%)
    • Table 5 Global Market for Enzyme Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 6 Global Market Share of Enzyme Inhibitors, by Region, 2016 (%)
    • Table 7 Global Market for Proton Pump Inhibitors, Through 2022 ($ Millions)
    • Table 8 Global Market Share of Proton Pump Inhibitors, by Region, 2016 (%)
    • Table 9 Global Market for Protease Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 10 Global Market Share of Protease Inhibitors, by Region, 2016 (%)
    • Table 11 Global Market for Reverse Transcriptase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 12 Global Market Share of Reverse Transcriptase Inhibitors, by Region, 2016 (%)
    • Table 13 Global Market for Kinase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 14 Global Market Share of Kinase Inhibitors, by Region, 2016 (%)
    • Table 15 Global Market for Statins, by Region, Through 2022 ($ Millions)
    • Table 16 Market Share of Statins, by Region, 2016 (%)
    • Table 17 Global Market for Aromatase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 18 Market Share of Aromatase Inhibitors, by Region, 2016 (%)
    • Table 19 Global Market for Phosphodiesterase 5 Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 20 Market Share of Phosphodiesterase 5 Inhibitors, by Region, 2016 (%)
    • Table 21 Global Market for Neuraminidase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 22 Global Market Share of Neuraminidase Inhibitors, by Region, 2016 (%)
    • Table 23 Global Market for ACE Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 24 Global Market Share of ACE Inhibitors, by Region, 2016 (%)
    • Table 25 Global Market for PARP Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 26 Global Market Share of PARP Inhibitors, by Region, 2016 (%)
    • Table 27 Global Market for Xanthine Oxidase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 28 Global Market Share of Xanthine Oxidase Inhibitors, by Region, 2016 (%)
    • Table 29 Global Market for Phosphodiesterase 4 Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 30 Global Market Share of Phosphodiesterase 4 Inhibitors, by Region, 2016 (%)
    • Table 31 Global Market for Cyclooxygenase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 32 Global Market Share of Cyclooxygenase Inhibitors, by Region, 2016 (%)
    • Table 33 Global Market for 5-Alpha Reductase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 34 Market Share of 5-Alpha Reductase Inhibitors, by Region, 2016 (%)
    • Table 35 Global Market for Dipeptidyl Peptidase-4 Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 36 Global Market Share of Dipeptidyl Peptidase-4 Inhibitors, by Region, 2016 (%)
    • Table 37 Global Market for SGLT-2 Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 38 Global Market Share of SGLT-2 Inhibitors, by Region, 2016 (%)
    • Table 39 Global Market for Integrase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 40 Global Market Share of Integrase Inhibitors, by Region, 2016 (%)
    • Table 41 Global Market for Monoamine Oxidase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 42 Market Share of Monoamine Oxidase Inhibitors, by Region, 2016 (%)
    • Table 43 Global Market for PCSK9 Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 44 Global Market Share of PCSK9 Inhibitors, by Region, 2016 (%)
    • Table 45 Global Market for Acetylcholinesterase Inhibitors, by Region, Through 2022 ($ Millions)
    • Table 46 Market Share of Acetylcholinesterase Inhibitors, by Region, 2016 (%)
    • Table 47 Global Market for Enzyme Inhibitors, by Disease Sectors, Through 2022 ($ Millions)
    • Table 48 Global Market Share of Enzyme Inhibitors, by Disease Sectors, 2016 (%)
    • Table 49 Global Market for Enzyme Inhibitors in Cardiovascular Disease, by Region, Through 2022 ($ Millions)
    • Table 50 Global Market for Enzyme Inhibitors in Gastrointestinal Disorders, by Region, Through 2022 Millions)
    • Table 51 Global Market for Enzyme Inhibitors in HIV/AIDS, by Region, Through 2022 ($ Millions)
    • Table 52 Global Market for Enzyme Inhibitors in Hepatitis, by Region, Through 2022 ($ Millions)
    • Table 53 Global Market for Enzyme Inhibitors in Cancer, by Region, Through 2022 ($ Millions)
    • Table 54 Global Market for Enzyme Inhibitors in Men's Health, by Region, Through 2022 ($ Millions)
    • Table 55 Global Market for Enzyme Inhibitors in Diabetes, by Region, Through 2022 ($ Millions)
    • Table 56 Global Market for Enzyme Inhibitors in Other Sectors, by Region, Through 2022 ($ Millions)
    • Table 57 Leading Manufacturers/Suppliers of Proton Pump Inhibitors, 2016
    • Table 58 Market Share of Leading Manufacturers/Suppliers of Proton Pump Inhibitors, 2016 (%)
    • Table 59 Leading Manufacturers/Suppliers of Protease Inhibitors, 2016
    • Table 60 Market Share of Leading Manufacturers/Suppliers of Protease Inhibitors, 2016 (%)
    • Table 61 Leading Manufacturers/Suppliers of Reverse Transcriptase Inhibitors, 2016
    • Table 62 Market Share of Leading Manufacturers/Suppliers of Reverse Transcriptase Inhibitors, 2016 (%)
    • Table 63 Leading Manufacturers/Suppliers of Kinase Inhibitors, 2016
    • Table 64 Market Share of Leading Manufacturers/Suppliers of Kinase Inhibitors, 2016 (%)
    • Table 65 Leading Manufacturers of Statins, 2016
    • Table 66 Market Share of Leading Manufacturers/Suppliers of Statins, 2016 (%)
    • Table 67 Leading Manufacturers/Suppliers of Aromatase Inhibitors, 2016
    • Table 68 Market Share of Leading Manufacturers/Suppliers of Aromatase Inhibitors, 2016 (%)
    • Table 69 Leading Manufacturers/Suppliers of Phosphodiesterase 5 Inhibitors, 2016
    • Table 70 Market Share of Leading Manufacturers/Suppliers of Phosphodiesterase 5 Inhibitors, 2016
    • Table 71 Leading Manufacturers/Suppliers of Neuraminidase Inhibitors, 2016
    • Table 72 Market Share of Leading Manufacturers/Suppliers of Neuraminidase Inhibitors, 2016 (%)
    • Table 73 Leading Manufacturers/Suppliers of Angiotensin-Converting Enzyme Inhibitors, 2016
    • Table 74 Market Share of Leading Manufacturers/Suppliers of Angiotensin-Converting Enzyme Inhibitors, 2016 (%)
    • Table 75 Leading Manufacturers/Suppliers of PARP Inhibitors, 2016
    • Table 76 Market Share of Leading Manufacturers/Suppliers of PARP Inhibitors, 2016 (%)
    • Table 77 Leading Manufacturers/Suppliers of Xanthine Oxidase Inhibitors, 2016
    • Table 78 Market Share of Leading Manufacturers/Suppliers of Xanthine Oxidase Inhibitors, 2016 (%)
    • Table 79 Leading Manufacturers/Suppliers of Phosphodiesterase 4 Inhibitors, 2016
    • Table 80 Market Share of Leading Manufacturers/Suppliers of Phosphodiesterase 4 Inhibitors, 2016
  • Table 81 Leading Manufacturers/Suppliers of Cyclooxygenase Inhibitors, 2016
  • Table 82 Market Share of Leading Manufacturers/Suppliers of Cyclooxygenase Inhibitors, 2016 (%)
  • Table 83 Leading Manufacturers/Suppliers of 5-Alpha Reductase Inhibitors, 2016
  • Table 84 Market Share of Leading Manufacturers/Suppliers of 5-Alpha Reductase Inhibitors, 2016 (%)
  • Table 85 Leading Manufacturers/Suppliers of Dipeptidyl Peptidase-4 Inhibitors, 2016
  • Table 86 Market Share of Leading Manufacturers/Suppliers of Dipeptidyl Peptidase-4 Inhibitors, 2016 (%)
  • Table 87 Leading Manufacturers/Suppliers of SGLT-2 Inhibitors, 2016
  • Table 88 Market Share of Leading Manufacturers/Suppliers of SGLT-2 Inhibitors, 2016 (%)
  • Table 89 Leading Manufacturers/Suppliers of Integrase Inhibitors, 2016
  • Table 90 Market Share of Leading Manufacturers/Suppliers of Integrase Inhibitors, 2016 (%)
  • Table 91 Leading Manufacturers/Suppliers of Monoamine Oxidase Inhibitors, 2016
  • Table 92 Market Share of Leading Manufacturers/Suppliers of Monoamine Oxidase Inhibitors, 2016 (%)
  • Table 93 Leading Manufacturers/Suppliers of PCSK9 Inhibitors, 2016
  • Table 94 Market Share of Leading Manufacturers/Suppliers of PCSK9 Inhibitors, 2016 (%)
  • Table 95 Leading Manufacturers/Suppliers of Acetylcholinesterase Inhibitors, 2016
  • Table 96 Market Share of Leading Manufacturers/Suppliers of Acetylcholinesterase Inhibitors, 2016 (%)
  • Table 97 Number of Patents Granted for Enzyme Inhibitors, by Year, 2015-March 2017
  • Table 98 Number of Patents Awarded for Enzyme Inhibitors, by Type, 2015-March 2017
  • Table 99 Number of Patents Awarded for Enzyme Inhibitors, by Company, 2015-March 2017
  • Table 100 Number of Patents Awarded for Enzymes Inhibitors, by Country, 2015-March 2017
  • Table 101 Patents Issued by Country for Enzyme Inhibitors, 2015-March 2017 (Number/%)
  • Table 102 Number of Patents for Enzyme Inhibitors, by Patent Assignee, 2015-March 2017
  • Table 103 New Drug Approvals for Enzyme Inhibitors, 2015-March 2017
  • Table 104 Pipeline Products for Enzyme Inhibitors, by Company as of March 2017
  • Table 105 Mergers and Acquisitions of Leading Pharmaceutical Companies in Enzyme Inhibitors, 2015-March 2017
  • Table 106 Abbreviations Used in Enzyme Inhibitors

List of Figures

  • Summary Figure: Global Market for Enzyme Inhibitors, by Type, 2015-2022 ($ Millions)
    • Figure 1 Global Market for Enzyme Inhibitors, by Type, 2015-2022 ($ Millions)
    • Figure 2 Global Market Share of Enzyme Inhibitors, by Type, 2016 (%)
    • Figure 3 Global Market for Enzyme Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 4 Global Market Share of Enzyme Inhibitors, by Region, 2016 (%)
    • Figure 5 Global Market for Proton Pump Inhibitors, 2015-2022 ($ Millions)
    • Figure 6 Global Market Share of Proton Pump Inhibitors, by Region, 2016 (%)
    • Figure 7 Global Market for Protease Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 8 Global Market Share of Protease Inhibitors, by Region, 2016 (%)
    • Figure 9 Global Market for Reverse Transcriptase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 10 Global Market Share of Reverse Transcriptase Inhibitors, by Region, 2016 (%)
    • Figure 11 Global Market for Kinase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 12 Global Market Share of Kinase Inhibitors, by Region, 2016 (%)
    • Figure 13 Global Market for Statins, by Region, 2015-2022 ($ Millions)
    • Figure 14 Market Share of Statins, by Region, 2016 (%)
    • Figure 15 Global Market for Aromatase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 16 Market Share of Aromatase Inhibitors, by Region, 2016 (%)
    • Figure 17 Global Market for Phosphodiesterase 5 Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 18 Market Share of Phosphodiesterase 5 Inhibitors, by Region, 2016 (%)
    • Figure 19 Global Market for Neuraminidase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 20 Global Market Share of Neuraminidase Inhibitors, by Region, 2016 (%)
    • Figure 21 Global Market for ACE Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 22 Global Market Share of ACE Inhibitors, by Region, 2016 (%)
    • Figure 23 Global Market for PARP Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 24 Global Market Share of PARP Inhibitors, by Region, 2016 (%)
    • Figure 25 Global Market for Xanthine Oxidase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 26 Global Market Share of Xanthine Oxidase Inhibitors, by Region, 2016 (%)
    • Figure 27 Global Market for Phosphodiesterase 4 Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 28 Global Market Share of Phosphodiesterase 4 Inhibitors, by Region, 2016 (%)
    • Figure 29 Global Market for Cyclooxygenase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 30 Global Market Share of Cyclooxygenase Inhibitors, by Region, 2016 (%)
    • Figure 31 Global Market for 5-Alpha Reductase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 32 Market Share of 5-Alpha Reductase Inhibitors, by Region, 2016 (%)
    • Figure 33 Global Market for Dipeptidyl Peptidase-4 Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 34 Global Market Share of Dipeptidyl Peptidase-4 Inhibitors, by Region, 2016 (%)
    • Figure 35 Global Market for SGLT-2 Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 36 Global Market Share of SGLT-2 Inhibitors, by Region, 2016 (%)
    • Figure 37 Global Market for Integrase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 38 Global Market Share of Integrase Inhibitors, by Region, 2016 (%)
    • Figure 39 Global Market for Monoamine Oxidase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 40 Market Share of Monoamine Oxidase Inhibitors, by Region, 2016 (%)
    • Figure 41 Global Market for PCSK9 Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 42 Global Market Share of PCSK9 Inhibitors, by Region, 2016 (%)
    • Figure 43 Global Market for Acetylcholinesterase Inhibitors, by Region, 2015-2022 ($ Millions)
    • Figure 44 Market Share of Acetylcholinesterase Inhibitors, by Region, 2016 (%)
    • Figure 45 Global Market for Enzyme Inhibitors, by Disease Sectors 2015-2022 ($ Millions)
    • Figure 46 Global Market Share of Enzyme Inhibitors, by Disease Sectors, 2016 (%)
    • Figure 47 Global Market for Enzyme Inhibitors in Cardiovascular Disease, by Region, 2015-2022 ($ Millions)
    • Figure 48 Global Market for Enzyme Inhibitors in Gastrointestinal Disorders, by Region, 2015-2022 ($ Millions)
    • Figure 49 Global Market for Enzyme Inhibitors in HIV/AIDS, by Region, 2015-2022 ($ Millions)
    • Figure 50 Global Market for Enzyme Inhibitors in Hepatitis, by Region, 2015-2022 ($ Millions)
    • Figure 51 Global Market for Enzyme Inhibitors in Cancer, by Region, 2015-2022 ($ Millions)
    • Figure 52 Global Market for Enzyme Inhibitors in Men's Health, by Region, 2015-2022 ($ Millions)
    • Figure 53 Global Market for Enzyme Inhibitors in Diabetes, by Region, 2015-2022 ($ Millions)
    • Figure 54 Global Market for Enzyme Inhibitors in Other Sectors, by Region, 2015-2022 ($ Millions)
    • Figure 55 Market Share of Leading Manufacturers/Suppliers of Proton Pump Inhibitors, 2016 (%)
    • Figure 56 Market Share of Leading Manufacturers/Suppliers of Protease Inhibitors, 2016 (%)
    • Figure 57 Market Share of Leading Manufacturers/Suppliers of Reverse Transcriptase Inhibitors, 2016 (%)
    • Figure 58 Market Share of Leading Manufacturers/Suppliers of Kinase Inhibitors, 2016 (%)
    • Figure 59 Market Share of Leading Manufacturers/Suppliers of Statins, 2016 (%)
    • Figure 60 Market Share of Leading Manufacturers/Suppliers of Aromatase Inhibitors, 2016 (%)
    • Figure 61 Market Share of Leading Manufacturers/Suppliers of Phosphodiesterase 5 Inhibitors, 2016 (%)
    • Figure 62 Market Share of Leading Manufacturers/Suppliers of Neuraminidase Inhibitors, 2016 (%)
    • Figure 63 Market Share of Leading Manufacturers/Suppliers of Angiotensin-Converting Enzyme Inhibitors, 2016 (%)
    • Figure 64 Market Share of Leading Manufacturers/Suppliers of Xanthine Oxidase Inhibitors, 2016 (%)
    • Figure 65 Market Share of Leading Manufacturers/Suppliers of Phosphodiesterase 4 Inhibitors, 2016
    • Figure 66 Market Share of Leading Manufacturers/Suppliers of Cyclooxygenase Inhibitors, 2016 (%)
    • Figure 67 Market Share of Leading Manufacturers/Suppliers of 5-Alpha Reductase Inhibitors, 2016 (%)
    • Figure 68 Market Share of Leading Manufacturers/Suppliers of Dipeptidyl Peptidase-4 Inhibitors, 2016 (%)
    • Figure 69 Market Share of Leading Manufacturers/Suppliers of SGLT-2 Inhibitors, 2016 (%)
    • Figure 70 Market Share of Leading Manufacturers/Suppliers of Integrase Inhibitors, 2016 (%)
    • Figure 71 Market Share of Leading Manufacturers/Suppliers of Monoamine Oxidase Inhibitors, 2016
    • Figure 72 Market Share of Leading Manufacturers/Suppliers of PCSK9 Inhibitors, 2016 (%)
    • Figure 73 Market Share of Leading Manufacturers/Suppliers of Acetylcholinesterase Inhibitors, 2016
    • Figure 74 Number of Patents Granted for Enzyme Inhibitors, by Year, 2015-March 2017
    • Figure 75 Patents Issued by Country for Enzyme Inhibitors, 2015-March 2017 (No./%)
    • Figure 76 Number of Patents for Enzyme Inhibitors, by Patent Assignee, 2015-March 2017
Back to Top